Table 1

Demographic and disease characteristics of the study population
All patients (number = 291) RA on MTX (number = 50) RA on anti-TNF monotherapy (number = 38) RA on anti-TNF + MTX (number = 53) RA on abatacept (number = 5) RA on rituximab (number = 10) RA on tocilizumab (number = 2) SpA on anti-TNF monotherapy (number = 41) SpA on anti-TNF + MTX (number = 51) SpA on NSAIDs/ analgesics controls (number = 41)
Age (years) mean (range) 57 (23 to 87) 62.3 (26 to 87) 62.4 (32 to 86) 61.1 (41 to 83) 55.2 (43 to 66) 62.3 (43 to 79) 63.5 (55 to 72) 49.0 (2 to 69) 52.6 (26 to 71) 52.2 (23 to 72)
Gender (% female) 64 78 84 80 86 80 100 37 51 51
Disease duration (years) mean (range) 16.0 (1 to 55) 12.5 (1 to 41) 21.1 (3 to 46) 18.2 (2 to 48) 12.4 (6 to 24) 22.3 (5 to 55) 21.5 (15 to 28) 16.6 (1 to 36) 13.1 (1 to 42) 14.3 (1 to 37)
RF positive (%) 43 76 87 76 100 80 100 ----- ----- ----
Anti-CCP positive (%) 43 82 74 83 80 80 50 ------ ----- ……
HLA-B27 positve (%) 22.3 ----- ------ ----- ------ ------- ------ 56 28 68

MTX, methotrexate; NSAIDS, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; SpA, spondylarthropathy.

Kapetanovic et al.

Kapetanovic et al. Arthritis Research & Therapy 2014 16:R2   doi:10.1186/ar4427

Open Data